Genetic Variants as Markers for Use in Diagnosis, Prognosis and Treatment of Eosinophilia, Asthma, and Myocardial Infarction

A method of genotyping a nucleic acid sample, comprising determining the identity of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from a human individual at risk for, or diagnosed with, myocardial infarction, wherein the marker is selected from the group consisting of rs3184504 and rs653178, and markers in linkage disequilibrium therewith, whereupon the identity of no more than 4 alleles is determined.

A method of predicting prognosis of an individual experiencing symptoms associated with, or an individual diagnosed with, myocardial infarction the method comprising

• obtaining sequence data about a human individual identifying at least one allele of at least one polymorphic marker selected from the group consisting of rs3184504, rs653178, and markers in linkage disequilibrium therewith, wherein different alleles of the at least one polymorphic marker are associated with different susceptibilities to myocardial infarction in humans, and
• predicting prognosis of the individual from the sequence data.

A method of assessing an individual for probability of response to a therapeutic agent for preventing, treating, and/or ameliorating symptoms associated with myocardial infarction, comprising:

• determining the identity of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the group consisting of rs3184504, rs653178, and markers in linkage disequilibrium therewith, wherein the identity of the at least one allele of the at least one marker is indicative of a probability of a positive response to the therapeutic agent.

A kit for assessing susceptibility to myocardial infarction of a human individual, the kit comprising reagents for selectively detecting at least one allele of at least one polymorphic marker in the genome of the human individual, wherein the polymorphic marker is selected from the group consisting of rs3184504 and rs653178, and markers in linkage disequilibrium therewith, and a collection of data comprising correlation data between the polymorphic markers and susceptibility to myocardial infarction.

Use of an oligonucleotide probe in the manufacture of a diagnostic reagent for diagnosing and/or assessing susceptibility to myocardial infarction, wherein the probe hybridizes to a segment of a nucleic acid whose nucleotide sequence is given by any of SEQ ID NOs:

• 1-681, wherein the segment is 15-500 nucleotides in length.

A computer-readable medium having computer executable instructions for determining susceptibility to myocardial infarction, the computer readable medium comprising:

• data indicative of at least one polymorphic marker;
• a routine stored on the computer readable medium and adapted to be executed by a processor to determine risk of developing myocardial infarction for the at least one polymorphic marker;
• wherein the at least one polymorphic marker is selected from the group consisting of rs3184504 and rs653178, and markers in linkage disequilibrium therewith.

An apparatus for determining a genetic indicator for myocardial infarction in a human individual, comprising:

• a processor
• a computer readable memory having computer executable instructions adapted to be executed on the processor to analyze marker and/or haplotype information for at least one human individual with respect to at least one polymorphic marker selected from the group consisting of rs3184504, rs653178, and markers in linkage disequilibrium therewith, and generate an output based on the marker or haplotype information, wherein the output comprises a measure of susceptibility of the at least one marker or haplotype as a genetic indicator of myocardial infarction for the human individual.

Use of an anti-myocardial infarction agent in the preparation of a medicament for treating myocardial infarction in a human individual that has been tested for (a) the presence of at least one allele of at least one polymorphic marker selected from the group consisting of rs3184504 and rs653178, and markers in linkage disequilibrium therewith, and/or (b) the presence of an amino acid substitution in an amino acid sequence encoded by the at least one marker.

A method of determining the safety and/or efficacy of a therapeutic agent used to treat myocardial infarction in a human individual, the improvement comprising obtaining sequence data about a human individual identifying at least one allele of at least one polymorphic marker selected from the group consisting of rs3184504 and rs653178, and markers in linkage disequilibrium therewith.

A method of diagnosing myocardial infarction in a human individual, comprising (A) one or a combination of:

• (i) considering the history of an illness and the symptoms experienced by the human individual, (ii) physically examining the human individual, (iii) conducting one or a combination of an electrocardiogram, a coronary angiogram, chest radiograph, echocardiogram on the human individual, (iv) testing blood of the human individual for cardiac markers, (v) detecting areas of reduced blood flow in conjunction with physiologic or pharmacologic stress, and (vi) determining the viability of tissue of the myocardium;
• and (B) obtaining sequence data identifying at least one allele of at least one polymorphic marker selected from the group consisting of rs3184504 and rs653178, and markers in linkage disequilibrium therewith.

-143. (canceled)